In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a new initiative to significantly reduce, refine, and replace animal testing ...
Stem Pharm, a Madison biotech startup, is using lab-created 3D "organoids" to develop a treatment for Alzheimer's disease. In April, the FDA and NIH announced plans to incentivize so-called "new ...
Hosted on MSN
Vivodyne Secures $40M Series A to Revolutionize Drug Discovery with Lab-Grown Human Tissues
SAN FRANCISCO, CA & PHILADELPHIA, PA — Vivodyne has raised $40 million in Series A funding to expand its cutting-edge robotics and AI platform, which uses lab-grown human tissues to transform ...
Feinberg Professor emerita Eva Redei’s research had two key components: vats of water and “depressed” rats. Redei found that the rodents, genetically engineered in a Kyoto lab to exhibit depressive ...
The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal antibodies and some other drug candidates. Animal testing will be "reduced, ...
Please provide your email address to receive an email when new articles are posted on . The FDA plans to reduce and potentially replace animal testing for developing monoclonal antibody therapies and ...
Researchers have built a realistic human mini spinal cord in the lab and used it to simulate traumatic injury. The model reproduced key damage seen in real spinal cord injuries, including inflammation ...
ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results